Hemant Kumar, Ph.D., is a Vice President of CMC at OncoImmune. He is an expert with over 25-year successful track record in advanced programs (early to late stage) for Biologic, AAV Gene and Cell Therapy, Vaccines, ADCs, and Biosimilars development, commercialization, and life-cycle-management experience. He has contributed to the successful GMP Mfg., BLA submissions and commercial launch of FDA approved products.
Prior to joining OncoImmune, he was a leader in Global Process Sciences & Clinical Manufacturing Operations at Rentschler-Biopharma; Head of CMC, Technical Development and Manufacturing Operations at AnaptysBio, Inc., and the Associate Vice President, CMC Bioprocess Development and Technical Services at Merck Biologics and Vaccines. Additionally, he held roles of increasing responsibility at Sanofi Genzyme, Lonza Biologics, Sanofi Pasteur, Ortho Biotech, and Wyeth-Lederle Vaccine, and was also a Postdoctoral Research Associate at Yale University School of Medicine, University of Rhode Island (CDC Center for Vaccine Development), and the University of New Mexico.
Hemant received his Ph.D. in Biochemistry and both his Master of Science and Bachelor of Science at J.N. Medical College, A.M University in Aligarh, India.